Clinical trials: Allogenetic Hematopoietic Stem Cell Transplantation
Leukemia, Myeloid, Acute
Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse
The goal of this clinical research study is to learn if azacitidine combined with Chidamide will help to control the disease in patients with high-risk AML after an allogeneic stem cell transplant.
- Trial name
- NCT05270200
- Testing
- Azacitidine, Chidamide
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhujiang Hospital
Antibacterial Prophylaxis, Hematological Malignancies
Antibacterial Prophylaxis vs no Prophylaxis for Hematological Malignancies Patients Before Allo-HSCT
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative treatment for a variety of hematologic malignancies.
- Conditions
- Antibacterial Prophylaxis, Hematological Malignancies, Allogenetic Hematopoietic Stem Cell Transplantation, Imipenem
- Trial name
- NCT03733340
- Testing
- Imipenem
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Nanfang Hospital, Southern Medical University
B ALL, Allogenetic Hematopoietic Stem Cell Transplantation
CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT
This prospective, open-label randomized controlled trial compares CD19 CAR-T therapy with chemotherapy plus donor lymphocyte infusion (DLI) in 70 patients with Ph-negative B-cell acute lymphoblastic leukemia (B-ALL) who exhibited…
- Conditions
- B ALL, Allogenetic Hematopoietic Stem Cell Transplantation, MRD-positive
- Trial name
- NCT07441291
- Testing
- CAR-T, DLI
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Peking University People's Hospital
Poor Graft Function
Eltrombopag For Secondary Poor Graft Function Post Allogeneic Hematopoietic Stem Cell Transplantation
To investigate the efficacy and safety for secondary poor graft function (PGF) post allogeneic hematopoietic stem cell transplantation (allo-HSCT). The primary objective is the hematologic response rate.
- Trial name
- NCT03437603
- Testing
- Eltrombopag
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Chronic Graft-versus-host Disease
MSC for Treatment of cGVHD After Allo-HSCT
The purpose of this study is to evaluate the efficacy of mesenchymal stem cells in patients with chronic graft-versus-host disease.
- Trial name
- NCT04692376
- Testing
- Mesenchymal stem cells, Glucocorticoids, cyclosporine
- Where
- China
- Volunteers
- 152 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Hematopoietic Stem Cell Transplantation, Low-Level Light Therapy
Low Power Laser Therapy As Prevention Of Oral Mucositis And Oropharyngeal Pain In Patients Undergoing Allogenetic HSCT
Objective: To compare the effects of two low-power laser therapy protocols (application of a wavelength in the mouth, red region and another in the neck infrared region X simultaneous dual application of two wavelengths, red and…
- Conditions
- Hematopoietic Stem Cell Transplantation, Low-Level Light Therapy, Stomatitis
- Trial name
- NCT06071637
- Testing
- Double low-power laser therapy simultaneous applicated
- Where
- 2 sites in Brazil
- Volunteers
- 84 people
- Sponsor
- Instituto Nacional de Cancer, Brazil
Minimal Residual Disease, Donor Lymphocyte Infusion
MRD-directed Donor Lymphocyte Infusion for Reduce of Relapse After Allo-HSCT
Allogeneic hematopoietic cell transplantation (Allo-HSCT) is an effective therapy for acute leukemia, but relapse remains an important problem.
- Conditions
- Minimal Residual Disease, Donor Lymphocyte Infusion, Hematopoietic Stem Cell Transplantation, Relapse
- Trial name
- NCT02673008
- Testing
- donor lymphocyte infusion
- Where
- China
- Volunteers
- 206 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Lung Diseases, Interstitial, Hematopoietic Stem Cell Transplantation
MSC for Treatment of Interstitial Lung Disease After Allo-HSCT
Interstitial lung disease (ILD） is the late pulmonary complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT) leading to high morbidity and mortality.
- Conditions
- Lung Diseases, Interstitial, Hematopoietic Stem Cell Transplantation, Bronchiolitis Obliterans
- Trial name
- NCT02543073
- Testing
- MSCs, AZM, Glucocorticoid
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders
RATIONALE: Giving chemotherapy drugs and total-body irradiation before a donor bone marrow transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem…
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00253552
- Testing
- filgrastim, busulfan, cyclophosphamide
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- OHSU Knight Cancer Institute
Minimal Residual Disease,Acute Leukemia, Hypomethylating Agents, Donor Lymphocyte Infusion, Allogeneic Hematopoietic Cell Transplantation
HMA+DLI vs DLI Preemptive Therapy Based on MRD for AL Undergoing Allo-HSCT
Allogeneic hematopoietic cell transplantation (Allo-HSCT) is an effective therapy for acute leukemia, but relapse is the most common problem affecting long-term survivors of allo-HSCT.
- Trial name
- NCT03662087
- Testing
- HMA+DLI, DLI
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Hematologic Malignancy, Stem Cell Transplant Complications
Beijing Protocol in Patients Receiving More Than 5/10 HLA-mismatched Allo-HSCT
The aim of the study is to evaluate the efficacy and safety of Beijing protocol in malignant haematologic disease patients receiving more than 5/10 HLA-mismatched allo-HSCT.
- Trial name
- NCT05921318
- Testing
- Beijing protocol
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking University People's Hospital
Iron Overload
Open-Label Single-Arm Pilot Study in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients With Transfusional Iron Overload
This study has been designed to establish the efficacy and safety of deferasirox in patients with iron overload from 6 to 18 months after allogeneic hematopoietic stem cell transplant (HSCT).
- Trial name
- NCT01335035
- Testing
- deferasirox
- Where
- 9 sites in Spain
- Volunteers
- 30 people
- Sponsor
- Novartis Pharmaceuticals